Optimizing NPS with Advanced Biomarker Solutions

Industry Pharma
Region North America & Europe
Solution Advanced Biomarker
Context
Biomarker-driven therapies have become a cornerstone of personalized medicine, significantly advancing the evolution of oncology treatments. Accurate and timely biomarker testing is essential for identifying patients who will benefit most from these therapies. Additionally, increasing the testing rate is a critical goal, as it expands the potential market for oncology drugs and ensures patients receive the most effective treatments. Advanced analytics and data science are pivotal in targeting specific patient populations and optimizing treatment processes. To address these challenges, pharma companies are leveraging these technologies and fostering innovation through ongoing research and strategic partnerships. These initiatives are crucial for achieving sustained success and driving advancements in the industry. 
Problem statement

Our client, a multinational pharmaceutical company, faced the challenge of varying biomarker testing rates across different cancers and regions, leading to inconsistent identification of patients who could benefit from targeted therapies. This inconsistency not only affected patient outcomes but also posed challenges for optimizing resource allocation. The key objective was to determine the quantitative impact of incremental increases in testing rates on NPS and to identify the most effective areas for intervention. Additionally, they also needed a solution that would streamline the biomarker testing process and improve overall cost-effectiveness in precision medicine. 

Impact

  • mNSCLC (PD-L1): A projected increase of 2,026 new patients with a 4% rise in testing rates highlighted the potential for significant gains in a large market. 
  • TNBC (PD-L1): The analysis indicated a potential increase of 2,054 new patients with an 11% increase in testing rates, suggesting a high-return area for targeted efforts. 
  • Endometrial Cancer (MSI/MMR): The potential addition of 1,640 new patients with a 12% increase in testing rates emphasized the value of focusing on under-tested areas. 

Access the Case Study to Learn More about This Partnership

Promo Effectiveness Measurement

The evolution of digital channels has revolutionized pharma marketing, providing expansive outreach for campaigns. Yet, assessing the success of marketing endeavors demands significant investment in fast, accurate, and flexible AI/ML techniques.

Read more

Retrieval Augmented Generation (RAG) Performance Enhancement

Market research plays a pivotal role in the growth strategy of pharmaceutical companies. However, as the volume of data generated continues to surge, traditional manual market research methods are becoming increasingly time-consuming and costly.

Read more

Control Tower for Strategic Decision-Making

MathCo built an executive dashboard for a biopharmaceutical major to maximize adoption and drive data-powered decision-making at scale.

Read more